JenaValve Technology, Inc.

JenaValve Technology, Inc. is a medical device company focused on developing the first transcatheter heart valve technology specifically designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System has gained approval in the EU for treating severe, symptomatic AR in high-risk patients, as well as for severe, symptomatic aortic stenosis. In the US, the company has completed enrollment of the ALIGN-AR IDE Clinical Trial, with potential to become the first and only TAVR system in the US for treating symptomatic severe AR upon approval.

Founded in 2006 and headquartered in Irvine, California, with additional offices in Leeds, U.K. and Munich, Germany, JenaValve has recently secured a $100.00M Series C investment on 31 August 2022. The leading investors in this round include GIMV, Qatar Investment Authority, Cormorant Asset Management, Innovatus Capital Partners, Valiance Advisors, Venture Incubator, Bain Capital Life Sciences, Andera Partners, RMM, and Peijia Medical.